This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
27 Jul 2011

First Medicine Approved in Canada for Hyponatremia

Health Canada has issued a notice of compliance for the first medicine approved in Canada for the treatment of hyponatremia.

Otsuka Canada Pharmaceutical Inc. announced yesterday that Health Canada has issued a notice of compliance for SAMSCA? (tolvaptan), the first medicine approved in Canada for the treatment of hyponatremia.

 

Hyponatremia is a condition in which a patient's blood level of sodium is abnormally low. Hyponatremia is the most common electrolyte disorder, and can be an important predictor of mortality in hospitalized patients.

 

SAMSCA is an oral, selective vasopressin V2-receptor antagonist, which was discovered and developed by Otsuka Pharmaceutical Co., Ltd. It is indicated to treat patients with clinically important, non-hypovolemic hyponatremia, e.g. serum sodium less than 130 mEq/L, or symptomatic hyponatremia.

Related News